Long-term cognitive and psychosocial outcomes in adults with phenylketonuria
- PMID: 34145605
- DOI: 10.1002/jimd.12413
Long-term cognitive and psychosocial outcomes in adults with phenylketonuria
Abstract
Previous studies have suggested that cognitive and psychosocial underfunctioning in early-treated adults with phenylketonuria (PKU) may be explained by suboptimal adherence to dietary treatments, however, these studies often employ small samples, with different outcome measures, definitions and cut-offs. Samples have also tended to comprise participants with a limited range of blood phenylalanine concentrations, and often individuals who may not have been treated early enough to avoid neurological damage. In this study, we explore the impact of lifetime dietary control, as indicated by blood phenylalanine concentrations in childhood, adolescence and adulthood, on long-term cognitive and psychosocial outcomes in a large sample of adults with PKU who were diagnosed by neonatal screening and commenced on dietary treatment within the first month of life. One hundred and fifty-four participants underwent cognitive testing, assessing attention, learning, working memory, language, executive functioning and processing speed. One hundred and forty-nine completed measures of psychosocial functioning, documenting educational, occupational, quality of life, emotional and social outcomes which were compared with a group of healthy controls. Many adults with PKU demonstrated cognitive impairments, most frequently affecting processing speed (23%), executive function (20%) and learning (12%). Cognitive outcomes were related to measures of historic metabolic control, but only processing speed was significantly related to phenylalanine concentration at the time of testing after controlling for historic levels. Adults with PKU did not, however, differ from controls in educational, occupational, quality of life or emotional outcomes, or on a measure of family functioning, and showed only minor differences in relationship style. These findings have implications for patient counselling and decisions regarding the management of PKU in adulthood.
Keywords: PKU; cognition; metabolic; neuropsychology; outcomes; phenylketonuria.
© 2021 SSIEM.
References
REFERENCES
-
- Loeber JG. Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007;30(4):430-438. https://doi.org/10.1007/s10545-007-0644-5.
-
- Brosco JP, Paul DB. The political history of PKU: reflections on 50 years of newborn screening. Pediatrics. 2013;132(6):987-989. https://doi.org/10.1542/peds.2013-1441.
-
- Eijgelshoven I, Demirdas S, Smith TA, van Loon JMT, Latour S, Bosch AM. The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands. Mol Genet Metab. 2013;109(3):237-242. https://doi.org/10.1016/j.ymgme.2013.05.003.
-
- Ahring K, Belanger-Quintana A, Doukoupil K, et al. Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur J Clin Nutr. 2011;65(2):275-278. https://doi.org/10.1038/ejcn.2010.258.
-
- Burlina AP, Lachmann RH, Manara R, et al. The neurological and psychological phenotype of adult patients with early-treated phenylketonuria: a systematic review. J Inherit Metab Dis. 2019;42(2):209-219. https://doi.org/10.1002/jimd.12065.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical